These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Short-term effects of morning versus evening dose of hydroxyzine 50 mg on cognition in healthy volunteers. Conen S; Theunissen EL; Vermeeren A; Ramaekers JG J Clin Psychopharmacol; 2011 Jun; 31(3):294-301. PubMed ID: 21508863 [TBL] [Abstract][Full Text] [Related]
25. Fixed drug eruption due to three antihistamines of a same chemical family: Cetirizine, levocetirizine, and hydroxyzine. Bhari N; Mahajan R; Singh S; Sharma VK Dermatol Ther; 2017 Mar; 30(2):. PubMed ID: 27612321 [No Abstract] [Full Text] [Related]
26. Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. Elzainy AA; Gu X; Simons FE; Simons KJ AAPS PharmSci; 2003 Nov; 5(4):E28. PubMed ID: 15198516 [TBL] [Abstract][Full Text] [Related]
27. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion. Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879 [TBL] [Abstract][Full Text] [Related]
28. Paradoxical exacerbation of chronic urticaria by H1-antihistamines and montelukast. Tedeschi A Eur Ann Allergy Clin Immunol; 2009 Dec; 41(6):187-9. PubMed ID: 20128233 [TBL] [Abstract][Full Text] [Related]
29. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. Monroe EW; Bernstein DI; Fox RW; Grabiec SV; Honsinger RW; Kalivas JT; Katz HI; Cuss F; Danzig MR; Garvin PR Arzneimittelforschung; 1992 Sep; 42(9):1119-21. PubMed ID: 1445478 [TBL] [Abstract][Full Text] [Related]
31. Multicenter study of the efficacy and safety of fexofenadine 60 mg. twice daily in 108 Thai patients with chronic idiopathic urticaria. Kulthanan K; Gritiyarangsan P; Sitakalin C; Charuwichitratana S; Korkij W; Aunhachoke K; Janjumratsang P; Jiamton S; Kuntiranont M; Krisadapong J; Gherunpong N; Kullavanijaya P J Med Assoc Thai; 2001 Feb; 84(2):153-9. PubMed ID: 11336071 [TBL] [Abstract][Full Text] [Related]
32. SOAP: solutions to often asked problems. Choice of antihistamines for urticaria. Alper BS Arch Fam Med; 2000 Aug; 9(8):748-51. PubMed ID: 10927716 [No Abstract] [Full Text] [Related]
33. Experience with cyclosporine in children with chronic idiopathic urticaria. Doshi DR; Weinberger MM Pediatr Dermatol; 2009; 26(4):409-13. PubMed ID: 19689515 [TBL] [Abstract][Full Text] [Related]
34. Acrivastine versus hydroxyzine in the treatment of cholinergic urticaria. A placebo-controlled study. Kobza Black A; Aboobaker J; Gibson JR; Harvey SG; Marks P Acta Derm Venereol; 1988; 68(6):541-4. PubMed ID: 2467496 [TBL] [Abstract][Full Text] [Related]
35. Dapsone hypersensitivity syndrome during delayed pressure urticaria treatment. do Valle SO; França AT; Pires GV; Guimarães P; Dias GA; Levy SA Ann Allergy Asthma Immunol; 2010 Feb; 104(2):181-2. PubMed ID: 20306824 [No Abstract] [Full Text] [Related]
36. Solar urticaria: a case with increased skin mast cells and good therapeutic response to an antihistamine. Rantanen T; Suhonen R Acta Derm Venereol; 1980; 60(4):363-5. PubMed ID: 6163290 [TBL] [Abstract][Full Text] [Related]
37. Treatment of systemic mastocytosis. Simon RA N Engl J Med; 1980 Jan; 302(4):231. PubMed ID: 6101289 [No Abstract] [Full Text] [Related]
38. [Bibliographic review of antihistaminics H2 in the treatment of chronic (or recurrent) idiopathic urticaria]. Gay G; Drouet M; Bonneau JC; Le Sellin J; Sabbah A Allerg Immunol (Paris); 1988 Dec; 20(10):377-8. PubMed ID: 2905603 [TBL] [Abstract][Full Text] [Related]
39. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases. Yagami A; Furue M; Togawa M; Saito A; Hide M J Dermatol; 2017 Apr; 44(4):375-385. PubMed ID: 27862227 [TBL] [Abstract][Full Text] [Related]
40. Omalizumab, an Anti-IgE mAb, receives approval for the treatment of chronic idiopathic/spontaneous urticaria. Wu KCP; Jabbar-Lopez ZK J Invest Dermatol; 2015 Jan; 135(1):13-15. PubMed ID: 25501377 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]